BioCentury
ARTICLE | Clinical News

Latest data show Lynparza's survival benefit in breast cancer

June 5, 2017 10:39 PM UTC

New data from the Phase III OlympiAD trial to treat breast cancer showed that PARP inhibitor Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) reduced the risk of disease progression or death by 42% compared with chemotherapy (HR=0.58; 95% CI: 0.43, 0.8; p=0.0009). Median progression-free survival (PFS) was 7 months for Lynparza vs. 4.2 months for chemotherapy.

AZ previously said Lynparza met OlympiAD's primary PFS endpoint. Data were presented at the American Society of Clinical Oncology meeting in Chicago (see BioCentury Extra, Feb. 17)...